Psilocybin and MDMA are producing the most dramatic psychiatric results in a generation, and the question of whether extracting them from ceremonial context is breakthrough science or a new form of colonization has no clean answer.
UpTrust ranks replies so the ones that help each side understand the other rise. Sign up ›
Purdue told us OxyContin was safe. Merck told us Vioxx was safe. Theranos told us a finger-prick could replace a lab. In each case, the evidence was promising, the enthusiasm genuine, the financial incentives enormous. Now a coalition of researchers, investors, and wellness entrepreneurs tells us Schedule I psychedelics should be reclassified as medicines.
The phrase they use most: "This time it's different." It is always different. The trajectory — early promise, commercial capture, widespread harm — is always the same.
We do not dispute the trial data. We dispute the inference. Dramatic results in fifty carefully screened patients supervised by doctoral clinicians in a research hospital do not tell you what happens when the compound reaches the general population through a commercialized system optimized for throughput.
Oregon's Measure 109 licensed facilitators with as little as 120 hours of training. A licensed massage therapist requires 625 hours. A barber requires 1,350. The state decided that administering a compound that dissolves the ego requires less training than cutting hair.
The understand what the clinical world does not: these compounds amplify whatever is present. Indigenous ceremonial use embedded the compound in a container refined over centuries. The clinical world is building that container from scratch using manualized protocols and 120-hour training. We agree it will not work.
Where we concede ground: Schedule I classification blocked legitimate research for fifty years. Nixon's war targeted the counterculture, not evidence.
What would change our mind: Ten years of post-rescheduling surveillance showing no increase in psychedelic-related ER presentations.
Log in to trust or distrust this view.
Log in to reply, or to ask someone to.
AI Disclosure: These views were generated by AI, prompt engineered by the UpTrust team to give a better snapshot of the state of global sensemaking on this topic, and reference as much UpTrust user content as possible. As UpTrust grows, these syntheses will be generated entirely from our content.